Increased expression of p38 mitogen-activated protein kinase is related to the acute renal lesions induced by gentamicin.
Mitogen-activated protein kinases (MAPK) may be involved in the pathogenesis of acute renal failure. This study investigated the expression of p-p38 MAPK and nuclear factor kappa B (NF-kappaB) in the renal cortex of rats treated with gentamicin. Twenty rats were injected with gentamicin, 40 mg/kg, i.m., twice a day for 9 days, 20 with gentamicin + pyrrolidine dithiocarbamate (PDTC, an NF-kappaB inhibitor), 14 with 0.15 M NaCl, i.m., twice a day for 9 days, and 14 with 0.15 M NaCl , i.m., twice a day for 9 days and PDTC, 50 mg kg(-1) day(-1), i.p., twice a day for 15 days. The animals were killed 5 and 30 days after the last of the injections and the kidneys were removed for histological, immunohistochemical and Western blot analysis and for nitrate determination. The results of the immunohistochemical study were evaluated by counting the p-p38 MAPK-positive cells per area of renal cortex measuring 0.05 mm2. Creatinine was measured by the Jaffé method in blood samples collected 5 and 30 days after the end of the treatments. Gentamicin-treated rats presented a transitory increase in plasma creatinine levels. In addition, animals killed 5 days after the end of gentamicin treatment presented acute tubular necrosis and increased nitrate levels in the renal cortex. Increased expression of p-p38 MAPK and NF-kappaB was also observed in the kidneys from these animals. The animals killed 30 days after gentamicin treatment showed residual areas of interstitial fibrosis in the renal cortex, although the expression of p-p38 MAPK in their kidneys did not differ from control. Treatment with PDTC reduced the functional and structural changes induced by gentamicin as well as the expression of p-p38 MAPK and NF-kappaB. The increased expression of p-p38 MAPK and NF-kappaB observed in these rats suggests that these signaling molecules may be involved in the pathogenesis of tubulointerstitial nephritis induced by gentamicin.
Volpini
R A
RA
Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
Balbi
A P C
AP
Costa
R S
RS
Coimbra
T M
TM
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D015153:Blotting, Western; D003404:Creatinine / Q000097:blood; D005260:Female; D005355:Fibrosis / Q000201:enzymology / Q000473:pathology; D005839:Gentamicins / Q000009:adverse effects*; D007150:Immunohistochemistry; D007672:Kidney Cortex / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology; D016328:NF-kappa B / Q000378:metabolism*; D009395:Nephritis, Interstitial / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology; D009566:Nitrates / Q000032:analysis; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013859:Thiocarbamates / Q000494:pharmacology; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D016328:NF-kappa B; D009566:Nitrates; D011759:Pyrrolidines; D013859:Thiocarbamates; C020972:pyrrolidine dithiocarbamic acid; D003404:Creatinine; D048051:p38 Mitogen-Activated Protein Kinases